THE CureVac announced today that it is abandoning the development of the first candidate vaccine of against him coronavirus, which had raised a lot of hope at first, but whose effectiveness proved to be frustrating, in order to focus on a new, more promising vaccine.
The company, which specializes in mRNA technology, “will focus its efforts on developing a second-generation Covid-19 vaccine” for which it is working with the British GSK and will therefore “withdraw” this vaccine from the current European Medicines Agency (EMA) screening process.
This “puts an end” to the pre-order agreement 405 million doses with the European Union, clarifies the company, which, however, continues discussions with Brussels on the “second generation” vaccine, according to AFP.
“The global fight against Covid-19 continues and we are determined to make a decisive contribution to it with a safe and effective vaccine,” he said. Franz-Werner Haas, CEO of CureVac, in a statement.
The German laboratory had announced in early July the final results of the large-scale clinical study showed efficiency of only 48%, a percentage well below that of the other Pfizer / BioNTech and Moderna mRNA vaccines.
CureVac and GSK say they want to start clinical trials of the second-generation vaccine in the coming months, variations.
An approval for the first vaccine would also not be possible “despite the first in the second trimester” next year, the statement said.
“We welcome the fact that CureVac is focusing its efforts on the promising second-generation vaccine.” CV2CoV, for which initial research shows “a clear improvement” over the first candidate vaccine, the CVnCoV, stated on his part the Reno Rapuoli, Scientific Director of GSK.
The biotechnology company, founded in 2000 by the researcher Ingmar Herr, a pioneer in messenger RNA research, was one of the first to launch the Covid-19 vaccine race.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
